» Download Public Reports
75 reports
- Company report
- November 2012
- 18 pages
... Chemistry, our productivity and future operating costs, the build-up of clinical development service capabilities, the growth of our biologics drug discovery and development capabilities, our expected ...
September 2012
... Uncertain as it depends upon the result of the clinical trial and the successful launching of the product. Should the outcome of the clinical trial and the launching of the product be unsuccessful ...
June 2012
... Joint workshop on early phase oncology clinical trials in china. The on was developed to engage medical professionals and investigators from top cancer hospitals and medical centers in china about ...
November 2012
... In drug discovery, while outsourcing non- strategic activities such as good laboratory practice toxicology and clinical supply manufacture. 2012 Drug r&d division financial performance: hmp revenues were ...
December 2012
... In 2012, as compared to $3,457,000 in 2011. The decrease in research and development spending relates to fewer patients enrolling in and remaining on clinical trials during 2012, as well as decreases ...
April 2013
... Refund : after completion of phase ii trial, if jiangsu neptunus decides not to proceed with the next clinical trial by reason of safety and effectiveness of the recombinant technology, shenzhen neptunus ...
April 2013
... D productivity by shortening drug-development times and delivering the highest-quality services. We work with our customers to provide them with the capabilities and capacity they need throughout the drug ...
October 2012
... Pharmaceuticals 49 Pharmaceutical companies < 10 employees; dominant larger companies such as teva drug discovery, drug delivery, nces 52 Biopharma companies conducting clinical trials covering 61 molecules ...
December 2012
... For the biomarkers market. - Important technologies being used in the discovery of biomarkers. - Promising biomarkers that are expected to be used in the drug discovery process in the future. Reasons to buy - develop ...
» Purchase Premium Reports
(From $ 750 - $ 2 000)
68 reports
- $ 2 000
- Industry report
- February 2013
- by Global Markets Direct
Varicella Zoster (HHV-3) Infections - Pipeline Review, H1 2013 Summary Global Markets Direct's, 'Varicella Zoster (HHV-3) Infections - Pipeline Review, H1 2013', provides an overview of the indication's ...
April 2013
$ 750
Summary Spineway is a medical device company. It specializes in design, development, manufacture and supply of implants for spinal column surgery. The company's products include posterior fusion system, ...
April 2013
$ 750
Since the reform and open door policy implemented by Chinese authorities in the late 1970s, the door of the Chinese drug market began opening up to the world step by step, which gave a fillip to the imported ...
April 2013
$ 750
Table of Contents Table of Contents.1 Preface.2 Chapter 1. Introduction.5 Chapter 2. The State Food and Drug Administration in China.6 2.1. SFDA's Main Responsibilities.6 2.2. SFDA's Organizational Structure..7 ...
May 2013
$ 750
Summary Perfint Healthcare Pvt. Ltd. (Perfint) is a medical device company. The company develops medical devices for the healthcare market. Its products include Maxio, Robio EX, Robio EZ and Robio. Robio ...
May 2013
$ 750
China Pharmaceutical Guidebook Series (3) 2013 Edition Material and Clinical Trial Requirements of Application and Approval for Imported Drug Registration: A Guidebook of Registration Application for Imported ...
